Current views of the risk factors, diagnosis, and therapy of Alzheimer's disease (according to the proceedings of the Alzheimer's Association International Conference, London, 2017)
Abstract
The paper presents an overview of new methods for the diagnosis, treatment, and prevention of Alzheimer's disease (AD) according to the proceeding of the Alzheimer's Association International Conference that was held in London on 16 to 20 July 2017. AD is the most common cause of dementia, especially in the elderly. The data of epidemiological and genetic studies and risk factors for AD were considered. Great attention was paid to the relationship of AD to cerebrovascular disorders, the differential diagnosis of AD with dementia in other nosological entities (dementia with Lewy bodies, frontotemporal dementia, cerebrovascular disease). New approaches to managing patients with AD were discussed. Current ideas about therapy for BA, symptomatic and pathogenetic methods for its treatment, combined therapy were outlined.
About the Author
N. N. Koberskaya
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
11, Rossolimo St., Moscow 119021
Department of Nervous System Diseases and Neurosurgery
References
1. Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, intervention, and care. Lancet. 2017 Jul 19. pii: S0140-6736(17) 31363-6. doi: 10.1016/S0140-6736(17)31363-6. [Epub ahead of print].
2. Onyike CU, Chaney GA. Alzheimer Disease at the Extremes of Age: Clinical Epidemiology, Diagnosis and Care. Alzheimer's Association International Conference, AAIC. London; 2017.
3. Fiford CM , Nicholas JM, Biessels GJ, et al. Simultaneous Changes in Blood Pressure, Cognition and Brain Volume in Ageing, Mild Cognitive Impairment and Alzheimer's Disease. Alzheimer's Association International Conference, AAIC. London; 2017.
4. Besser LM, Nation DA, Hughes TM, et al. Pulse Pressure in Late-Life and Alzheimer's and Cerebrovascular Neuropathology. Alzheimer's Association International Conference, AAIC. London; 2017.
5. Jicha GA, Al-Janabi O, Bahrani A, et al. Cerebrovascular Disease and Alzheimer's Disease, but Not Aging, Are Associated with Moderate to Severe Global Cerebral Atrophy Seen on Clinical Brain Imaging Studies. Alzheimer's Association International Conference, AAIC. London; 2017.
6. Brickman AM, Tosto G, Gutierrez J, et al. The Impact of Cerebrovascular Disease and Neurodegeneration in Alzheimer's Disease. Alzheimer's Association International Conference, AAIC. London; 2017.
7. Hilal S, Akoudad S, van Duijn CM, et al. Plasma Amyloid Beta Levels, Cerebral Small Vessel Diseases and Cognition – the Rotterdam Study. Alzheimer's Association International Conference, AAIC. London; 2017.
8. Windham BG, Wilkening SR, Tingle JV, et al. Relationships of Very Small, Infarct-like Lesions with 20-Year Cognitive Decline: The ARIC Study. Alzheimer's Association International Conference, AAIC. London; 2017.
9. Ding J, Sigurdsson S, van Buchem M, et al. Total MRI Burden of Cerebral Small Vessel Disease Is Associated with Cognitive Decline and an Increased Risk of Dementia in Older People: The Ages-Reykjavik Study. Alzheimer's Association International Conference, AAIC. London; 2017.
10. Kapasi A, Leurgans SE, Boyle PA, et al. Watershed Microinfarct Pathology and Cognition in Older Persons. Alzheimer's Association International Conference, AAIC. London; 2017.
11. Nation DA, Tan A, McIntosh EC, et al. Circulating Angiogenic Cell Levels Show Protective Associations with Memory Function: Introducing the Vascular Reserve Hypothesis. Alzheimer's Association International Conference, AAIC. London; 2017.
12. Flanigan PM, Khosravi MA, Leverenz JB, et al. Color Vision Impairment in Dementia with Lewy Bodies: A Novel and Highly Specific Distinguishing Feature from Alzheimer Dementia. Alzheimer's Association International Conference, AAIC. London; 2017.
13. Botzung A, Philippi N, Constans-Erbs M, et al. Insular Cognitive Impairment in Early Dementia with Lewy Bodies. Alzheimer's Association International Conference, AAIC. London; 2017.
14. Rus T, Jamsek J, Jensterle L, et al. Monitoring the Progression of Dementia Using FGD-PET Brain Imaging and Network Analysis: Role of the Alzheimer's Disease Related Pattern. Alzheimer's Association International Conference, AAIC. London; 2017.
15. Festari C, Altomare D, Walker Z, et al. Diagnostic Utility of FDG-PET in Differentiating Between Lewy Body Dementia and Fronto-Temporal Lobar Degeneration. Alzheimer's Association International Conference, AAIC. London; 2017.
16. van der Zande J, Gouw AA, Scheltens P, et al. Discrimination between Dementia with Lewy Bodies (DLB), Alzheimers' Disease (AD) and Mixed Pathology Using Electro-Encephalography (EEG). Alzheimer's Association International Conference, AAIC. London; 2017.
17. Paraskevaidi M, Morais CL, Lima KM, et al. Vibrational Spectroscopy of Blood Plasma for the Diagnosis of Alzheimer's Disease and Differentiation from Dementia with Lewy Bodies. Alzheimer's Association International Conference, AAIC. London; 2017.
18. Mishina M, Ishii K, Ishibashi K, et al. Regional Difference of Brain β-Amyloid Accumulation Between in Subtype of Lewy Body Disease and in Alzheimer's Disease. Alzheimer's Association International Conference, AAIC. London; 2017.
19. Chatterjee M, Lemstra AW, van Steenoven I, et al. Contactin-1 in CSF Discriminates Dementia with Lewy Bodies (DLB) from AD and Non-Demented Controls. Alzheimer's Association International Conference, AAIC. London; 2017.
20. Singh P, Miller V. Steady-State Clinical Pharmacokinetics Demonstrating Once-Weekly CorplexTM Donepezil Transdermal System as a Therapeutic Alternative to Daily Oral Aricept. Alzheimer's Association International Conference, AAIC. London; 2017.
21. Chertkow H, Feldman HH, Jcova C, et al. Definitions of dementia and predementia states in Alzheimer's disease and vascular cognitive impairment: consensus from the Canadian conference on diagnosis of dementia. Alzheimers Res Ther. 2013 Jul 8;5(Suppl 1):S2. doi: 10.1186/alzrt198. Epub 2013 Jul 8.
22. Albert MS, Dekosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging and Alzheimer's Association workgroup. Alzheimers Dement. 2011 May;7(3):270-9. doi: 10.1016/j.jalz.2011. 03.008. Epub 2011 Apr 21.
23. Atri A, Molinuevo JL, Lemming O, et al. Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy. Alzheimers Res Ther. 2013 Jan 21;5(1):6. doi: 10.1186/alzrt160. eCollection 2013.
24. Tariot PT, Farlow MR, Grossberg GR, et al. Memantine Treatment in Patients With Moderate to Severe Alzheimer Disease Already Receiving Donepezil: A Randomized Controlled Trial. JAMA. 2004 Jan 21;291(3): 317-24.
25. Inoue Y, Ueda M, Masuda T, et al. Memantine Attenuates Vascular Amyloid β Deposits and Spontaneous Hemorrhages in Mouse Models of Cerebral Amyloid Angiopathy. Alzheimer's Association International Conference, AAIC. London; 2017.
26. Atri A, Cummings JL, Hendrix S, et al. Maintenance of Cognitive Improvement Treatment Response with Memantine and Donepezil: Post Hoc Analyses from a PlaceboControlled Study in Patients with Moderate to Severe Alzheimer's Diseas. Alzheimer's Association International Conference, AAIC. London; 2017.
27. Wong D, Bellyou M, Beauchet O, et al. Vitamin D Supplementation May Protect Against Oxidative Stress in a Vitamin D Deficient Double-Transgenic Mouse Model of Alzheimer's Disease. Alzheimer's Association International Conference, AAIC. London; 2017.
28. Wong D, Bellyou M, Beauchet O, et al. Combined Memantine and Vitamin D Treatment Provides the Same Cognitive Benefit As Memantine Alone in a Chronically Vitamin D Deficient Double-Transgenic Mouse Model of Alzheimer's Disease. Alzheimer's Association International Conference, AAIC. London; 2017.
29. Cholet N, Foucquier J, Murphy N, et al. A Combination of Acamprosate and Baclofen (PXT864) Synergizes with Standards of Care for the Treatment of Alzheimer's Disease. Alzheimer's Association International Conference, AAIC. London; 2017.
30. Zung SP, Cuperman-Pohl T, Costa Morais D, et al. Fixed-Dose Combination of Donepezil Hydrochloride and Memantine Hydrochloride for Treatment of Moderate to Severe Alzheimer's Disease. Alzheimer's Association International Conference, AAIC. London; 2017.
31. Espindola S, Damianich A, Sartor M, et al. Phenotypic Rescue in a Mouse Model of Tauopathy By Early Modulation of Tau Isoforms Relative Content. Avale et al., 2013, Lacovich et al., 2016. Alzheimer's Association International Conference, AAIC. London; 2017.
32. Lacovich V, Espindola SL, Alloatti M, et al. Tau isoforms imbalance impairs the axonal transport of the amyloid precursor protein in human neurons. J Neurosci. 2017 Jan 4;37(1):58-69. doi: 10.1523/JNEUROSCI.2305-16.2016.
33. Medina YI, Carbonell F, Sotero RC, et al. Identifying and Reversing Multifactorial Interactive Mechanisms in Alzheimer's Disease. Alzheimer's Association International Conference, AAIC. London; 2017.
34. Crossley NA, Mechelli A, Scott J, et al. The hubs of the human connectome are generally implicated in the anatomy of brain disorders. Brain. 2014 Aug;137(Pt 8):2382-95. doi: 10.1093/brain/awu132. Epub 2014 Jun 19.
35. Iturria-Medina Y, Evans AC. On the central role of brain connectivity in neurodegenerative disease progression. Front Aging Neurosci. 2015 May 21;7:90. doi: 10.3389/fnagi.2015.00090. eCollection 2015.
36. Touchon J, Ousset PJ, Pasquier FE, et al. Treatment with Pxt-864 Showed Stabilisation of Cognitive Disability in Mild Alzheimer's Disease after 36 Weeks. Alzheimer's Association International Conference, AAIC. London; 2017.
37. Iizuka T, Kameyama M. Preventive Effect of Rifampicin on Alzheimer's Disease Needs at Least 450 Mg Daily for One Year: An FDGPET Follow-up Study. Alzheimer's Association International Conference, AAIC. London; 2017.
38. Kosaraju J, Tam KY, Basavan D. Novel Dual GLP-1 and Gip Receptor Analog Attenuates High-Fat-Diet Induced Disease Progression in 3xTg-AD Mice. Alzheimer's Association International Conference, AAIC. London; 2017.
39. Morgan D. Innovative Alzheimer's Drugs Offer Hope for Alzheimer's Patients and Families: An Analysis of the Phase 2 and Phase 3 Alzheimer's Drug Pipeline. Alzheimer's Association International Conference, AAIC. London; 2017.
For citation:
Koberskaya N.N. Current views of the risk factors, diagnosis, and therapy of Alzheimer's disease (according to the proceedings of the Alzheimer's Association International Conference, London, 2017). Neurology, Neuropsychiatry, Psychosomatics. 2017;9(3):81-87. (In Russ.) https://doi.org/10.14412/2074-2711-2017-3-81-87
Views: 336
Email this article 